Healthcare · Medical - Equipment & Services
Price
$102.42
Market Cap
$565.9M
Employees
741
Beta
0.93
Avg Volume
167,314
CEO
Gary Owens
Business Description
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
83.95
Stock Price: $102.42
EPS (Diluted): 1.22
EPS (Diluted): 1.22
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.62
Stock Price: $102.42
Total Equity: $186.25M
Shares: 5,565,000
Total Equity: $186.25M
Shares: 5,565,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
17.84
Market Cap: $565.86M
Total Debt: $151.48M
Cash: $26.93M
EBITDA: $35.29M
Total Debt: $151.48M
Cash: $26.93M
EBITDA: $35.29M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$629.5M
Market Cap: $565.86M
Total Debt: $151.48M
Cash: $26.93M
Total Debt: $151.48M
Cash: $26.93M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
63.5%
Gross Profit: $158.27M
Revenue: $249.13M
Revenue: $249.13M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
7.4%
Operating Income: $18.51M
Revenue: $249.13M
Revenue: $249.13M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
2.7%
Net Income: $6.71M
Revenue: $249.13M
Revenue: $249.13M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
3.6%
Net Income: $6.71M
Total Equity: $186.25M
Total Equity: $186.25M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
3.3%
Operating Income: $18.51M
Tax Rate: 44.1%
Equity: $186.25M
Total Debt: $151.48M
Cash: $26.93M
Tax Rate: 44.1%
Equity: $186.25M
Total Debt: $151.48M
Cash: $26.93M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.72
Current Assets: $106.27M
Current Liabilities: $61.90M
Current Liabilities: $61.90M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.81
Short-Term Debt: $5.63M
Long-Term Debt: $145.86M
Total Debt: $151.48M
Total Equity: $186.25M
Long-Term Debt: $145.86M
Total Debt: $151.48M
Total Equity: $186.25M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$44.77
Revenue: $249.13M
Shares: 5,565,000
Shares: 5,565,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$33.47
Total Equity: $186.25M
Shares: 5,565,000
Shares: 5,565,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$7.11
Operating CF: $42.83M
CapEx: -$3.25M
Shares: 5,565,000
CapEx: -$3.25M
Shares: 5,565,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.7%
Last Dividend: N/A
Stock Price: $102.42
Stock Price: $102.42
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $6.71M
Net Income: $6.71M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MLAB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 11:56am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $184.3M | $219.1M | $216.2M | $241.0M | $249.1M |
| Cost of Revenue | $75.2M | $85.4M | $82.9M | $90.1M | $90.9M |
| Gross Profit | $109.1M | $133.7M | $133.3M | $150.9M | $158.3M |
| Operating Expenses | $104.4M | $130.4M | $405.3M | $134.5M | $139.8M |
| Operating Income | $4.7M | $3.3M | -$272.1M | $16.3M | $18.5M |
| Net Income | $1.9M | $930,000 | -$254.2M | -$2.0M | $6.7M |
| EBITDA | $32.5M | $37.5M | -$238.4M | $42.3M | $35.3M |
| EPS | $0.36 | $0.17 | $-47.20 | $-0.36 | $1.22 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 11:56am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $49.3M | $32.9M | $28.2M | $27.3M | $26.9M |
| Total Current Assets | $124.3M | $119.0M | $109.4M | $102.7M | $106.3M |
| Total Assets | $707.4M | $661.8M | $446.8M | $433.3M | $427.7M |
| Current Liabilities | $48.1M | $43.4M | $44.3M | $164.0M | $61.9M |
| Long-Term Debt | $218.4M | $183.3M | $221.7M | $76.9M | $145.9M |
| Total Liabilities | $313.6M | $268.4M | $301.4M | $273.5M | $241.5M |
| Total Equity | $393.8M | $393.5M | $145.4M | $159.8M | $186.2M |
| Retained Earnings | $76.7M | $74.2M | -$183.5M | -$188.9M | -$185.7M |
Cash Flow (Annual)
Last updated: Jun 22, 2026 11:56am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $39.2M | $28.0M | $44.1M | $46.8M | $42.8M |
| Capital Expenditure | -$4.4M | -$4.5M | -$2.6M | -$4.5M | -$3.3M |
| Free Cash Flow | $34.8M | $23.4M | $41.6M | $42.3M | $39.6M |
| Acquisitions (net) | -$300.8M | -$5.0M | -$78.7M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$214.5M | -$16.4M | -$4.7M | $-893,000 | $-393,000 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 12:05am (8h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$250.6M $249.3M – $252.5M
|
$259.2M $257.8M – $261.1M
|
$272.2M $270.0M – $276.5M
|
$280.9M $279.5M – $283.0M
|
| EBITDA |
-$16.8M -$16.9M – -$16.7M
|
-$17.4M -$17.5M – -$17.3M
|
-$18.2M -$18.5M – -$18.1M
|
-$18.8M -$19.0M – -$18.7M
|
| Net Income |
$50.5M $50.1M – $50.9M
|
$65.7M $65.1M – $66.2M
|
$68.9M $68.3M – $69.5M
|
$0 |
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 11:56am (4d ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue Growth | +18.8% | -1.3% | +11.5% | +3.4% |
| Gross Profit Growth | +22.6% | -0.3% | +13.2% | +4.9% |
| Operating Income Growth | -29.4% | -8,295.0% | +106.0% | +13.3% |
| Net Income Growth | -50.3% | -27,438.3% | +99.2% | +440.0% |
| EBITDA Growth | +15.3% | -735.4% | +117.8% | -16.7% |
Dividend History (Last 20)
Last updated: Jun 22, 2026 11:56am (4d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-29 | $0.16 | 2026-04-02 | 2026-05-29 | 2026-06-15 |
| 2026-02-27 | $0.16 | 2026-01-07 | 2026-02-28 | 2026-03-16 |
| 2025-11-28 | $0.16 | 2025-10-03 | 2025-11-28 | 2025-12-15 |
| 2025-08-29 | $0.16 | 2025-07-03 | 2025-08-29 | 2025-09-15 |
| 2025-05-30 | $0.16 | 2025-04-07 | 2025-05-30 | 2025-06-16 |
| 2025-02-28 | $0.16 | 2025-01-06 | 2025-02-28 | 2025-03-17 |
| 2024-11-29 | $0.16 | 2024-10-02 | 2024-11-29 | 2024-12-16 |
| 2024-08-30 | $0.16 | 2024-07-08 | 2024-08-30 | 2024-09-16 |
| 2024-05-31 | $0.16 | 2024-04-02 | 2024-05-31 | 2024-06-14 |
| 2024-02-28 | $0.16 | 2024-01-02 | 2024-02-29 | 2024-03-15 |
| 2023-11-29 | $0.16 | 2023-10-03 | 2023-11-30 | 2023-12-15 |
| 2023-08-30 | $0.16 | 2023-07-05 | 2023-08-31 | 2023-09-15 |
| 2023-05-30 | $0.16 | 2023-04-03 | 2023-05-31 | 2023-06-15 |
| 2023-02-27 | $0.16 | 2023-01-03 | 2023-02-28 | 2023-03-15 |
| 2022-11-29 | $0.16 | 2022-10-03 | 2022-11-30 | 2022-12-15 |
| 2022-08-30 | $0.16 | 2022-07-06 | 2022-08-31 | 2022-09-15 |
| 2022-05-27 | $0.16 | 2022-04-06 | 2022-05-31 | 2022-06-15 |
| 2022-02-25 | $0.16 | 2022-01-06 | 2022-02-28 | 2022-03-15 |
| 2021-11-29 | $0.16 | 2021-10-01 | 2021-11-30 | 2021-12-15 |
| 2021-08-30 | $0.16 | 2021-07-06 | 2021-08-31 | 2021-09-15 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MLAB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for MLAB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30